Importance Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal
premature aging disease. There is no approved treatment. Objective To evaluate the …

Background—Hutchinson-Gilford progeria syndrome is an ultrarare segmental premature
aging disease resulting in early death from heart attack or stroke. There is no approved …

Hutchinson-Gilford progeria syndrome (HGPS) is characterized by clinical features that
typically develop in childhood and resemble some features of accelerated aging. Children …

Background: Hutchinson-Gilford progeria syndrome is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA yielding the farnesylated …

Hutchinson–Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental
premature aging syndrome caused by a mutation in LMNA that produces the farnesylated …

OBJECTIVES. Hutchinson-Gilford progeria syndrome is a rare and uniformly fatal segmental
“premature aging” disease that affects a variety of organ systems. We sought to more clearly …

Lonafarnib (Zokinvy™) is an orally active farnesyltransferase inhibitor developed by Eiger
BioPharmaceuticals under license from Merck & Co. for the treatment of hepatitis D virus …

Progeria is characterized by clinical features that mimic premature ageing. Although the
mutation responsible for this syndrome has been deciphered, the mechanism of its action …

Hutchinson–Gilford progeria syndrome (HGPS) is a progeroid syndrome characterized by
multiple aging-like disease phenotypes. We recently reported that a protein …

Background Hutchinson–Gilford progeria syndrome is a rare, sporadic, autosomal dominant
syndrome that involves premature aging, generally leading to death at approximately 13 …